#1 Clinical Trials Search in Europe

Retinol Acetate

This article discusses the use of Retinol Acetate, also known as QLT091001, in clinical trials for various eye conditions. These trials aim to evaluate the safety and efficacy of this drug in treating disorders such as Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa (RP), and impaired dark adaptation. The studies explore different dosing regimens and their potential to improve visual function in patients with these challenging eye conditions.

Table of Contents

What is Retinol Acetate?

Retinol Acetate, also known as QLT091001, is an experimental drug being studied for the treatment of certain inherited eye disorders[1]. It is a type of retinoid, which means it is related to vitamin A. Retinoids play a crucial role in maintaining healthy vision.

Conditions Treated

QLT091001 is being investigated for the treatment of two main inherited retinal diseases:

  • Leber Congenital Amaurosis (LCA): A rare genetic disorder that causes severe vision loss or blindness from birth[2].
  • Retinitis Pigmentosa (RP): A group of inherited eye disorders that cause progressive vision loss[3].

Both of these conditions are caused by mutations in specific genes, particularly the RPE65 and LRAT genes, which are important for the proper functioning of the retina (the light-sensitive tissue at the back of the eye)[3].

How It Works

QLT091001 is designed to replace a crucial molecule in the visual cycle that is missing or deficient in patients with LCA and RP due to RPE65 or LRAT mutations. By providing this missing component, the drug aims to improve visual function in these patients[3].

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and effectiveness of QLT091001:

  • A Phase 1b study assessed the drug’s ability to improve visual function in patients with LCA or RP after a 7-day treatment course[3].
  • Another trial investigated the effects of repeated treatments (up to 3 additional courses) in patients who had previously received a single 7-day course[2].
  • A study focused specifically on patients with RP caused by mutations in the RPE65 gene[1].
  • A Phase 2a study examined the drug’s effects on adults with impaired dark adaptation, which is the ability of the eye to adjust to low light conditions[5].

Administration

QLT091001 is administered orally (by mouth) once daily for 7 days[1]. The exact dosage may vary depending on the specific study and patient characteristics. In some trials, multiple treatment courses were given, with each course separated by a period of time[2].

Safety and Side Effects

As with any experimental drug, safety is a primary concern in the clinical trials of QLT091001. Researchers closely monitor patients for any adverse events (side effects) during and after treatment. Common assessments include:

  • Clinical laboratory tests
  • Electrocardiograms (ECGs) to monitor heart function
  • Vital signs
  • Visual acuity tests
  • Color vision tests[4]

It’s important to note that as an experimental drug, the full range of potential side effects may not yet be known. Patients participating in clinical trials are closely monitored by healthcare professionals to ensure their safety.

Aspect Details
Drug Name Retinol Acetate (QLT091001)
Administration Oral, typically once daily for 7 days
Conditions Studied Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa (RP), Impaired Dark Adaptation
Genetic Targets RPE65 and LRAT mutations
Primary Objectives Evaluate safety, improve visual function, assess duration of improvements
Outcome Measures Visual acuity, dark adaptation time, adverse events, clinical laboratory tests
Study Designs Phase 1 and 2 trials, including open-label and placebo-controlled studies
Patient Populations Adults and children with specific genetic eye disorders, healthy volunteers for safety studies

FAQ

  • What is QLT091001 and what conditions is it being tested for? QLT091001 is a form of Retinol Acetate being tested in clinical trials for eye conditions such as Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa (RP), and impaired dark adaptation. These are genetic disorders that affect vision and can lead to severe visual impairment or blindness.
  • How is QLT091001 administered in these trials? In most of the trials, QLT091001 is administered orally once daily for 7 days. Some studies are exploring repeated treatments or different dosing regimens to evaluate long-term effects and optimal dosing strategies.
  • What are the main goals of these clinical trials? The main goals of these trials are to evaluate the safety of QLT091001, assess whether it can improve visual function in patients with specific eye conditions, and determine the duration of any observed improvements in vision.
  • Are there any specific genetic mutations being targeted in these trials? Yes, some trials are specifically looking at patients with mutations in genes such as RPE65 (Retinal Pigment Epithelial 65 Protein) or LRAT (Lecithin:Retinol Acyltransferase). These mutations are associated with certain forms of LCA and RP.
  • How is the effectiveness of QLT091001 being measured in these trials? The effectiveness is being measured through various visual function tests, including visual acuity, dark adaptation time, and other specialized assessments of vision. Researchers are also monitoring for any adverse events and conducting safety assessments throughout the trials.

Ongoing Clinical Trials on Retinol Acetate

  • Study on the Effects of Pentoxifylline, Retinol Acetate, and DL-Alpha Tocopherol Acetate for Patients with Medication-Related Osteonecrosis of the Jaw

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Retinol Acetate (QLT091001): A form of vitamin A being studied as a potential treatment for certain genetic eye disorders. It is administered orally in these clinical trials.
  • Leber Congenital Amaurosis (LCA): A rare inherited eye disorder that primarily affects the retina, causing severe vision loss or blindness from birth or early childhood.
  • Retinitis Pigmentosa (RP): A group of rare genetic disorders that involve a breakdown and loss of cells in the retina, leading to progressive vision loss.
  • RPE65 (Retinal Pigment Epithelial 65 Protein): A protein crucial for the visual cycle in the eye. Mutations in the gene that produces this protein can lead to certain forms of LCA and RP.
  • LRAT (Lecithin:Retinol Acyltransferase): An enzyme involved in vitamin A metabolism in the eye. Mutations in the LRAT gene can cause certain types of LCA and RP.
  • Dark Adaptation: The process by which the eye adjusts to low light conditions. Impaired dark adaptation can be a symptom of various eye disorders.
  • Visual Acuity: A measure of the sharpness or clarity of vision, often tested using an eye chart.
  • Biofilm: A thin, slimy film of bacteria that adheres to a surface. In the context of skin ulcers, biofilms can impede healing and are a target for treatment.

References

  1. https://clinicaltrials.gov/study/NCT01543906
  2. https://clinicaltrials.gov/study/NCT01521793
  3. https://clinicaltrials.gov/study/NCT01014052
  4. https://clinicaltrials.gov/study/NCT00765427
  5. https://clinicaltrials.gov/study/NCT01999764